Hemostatic agents market seen reaching $5.71B by 2030

The hemostatic agents market is projected to grow from $4.66 billion in 2026 to $5.71 billion by 2030, driven by rising surgery volumes, new product formats and tighter safety requirements. North America held the largest market share in 2025, while the report flags broader use in minimally invasive, orthopedic, trauma and cardiovascular procedures.

Why it matters: - Hemostatic agents help control bleeding during surgery, which can reduce blood loss and improve the surgical field. - Demand for these products is tied to the global rise in surgical procedures and the need for safer, more efficient operating-room tools. - The market’s growth signals continued investment in products that support faster clotting and better procedural outcomes.

What happened: - The Business Research Company projected the hemostatic agents market will rise from $4.66 billion in 2026 to $5.71 billion by 2030. - The forecast implies a 5.2% compound annual growth rate over the period. - The market is expected to grow from $4.42 billion in 2025 to $4.66 billion in 2026, a 5.4% CAGR in the historical period described in the report. - North America held the largest share of the hemostatic agents market in 2025. - The report also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - A free sample of the report is available here. - The full report is available here.

The details: - Historical growth was linked to limited product variety, heavy reliance on thrombin and gelatin-based agents, rising surgery volumes, expanding hospital infrastructure and greater awareness of blood-loss management. - Future growth is expected to be supported by recombinant and sprayable fibrin sealants, more minimally invasive and orthopedic surgeries, wider use of multi-agent and combination products, and expanding applications in plastic surgery and neurosurgery. - The report also points to stricter regulatory focus on product sterility and biocompatibility. - Key trends include stronger adoption of advanced hemostats in surgery, broader use of combination therapies, more biologically derived fibrin sealants, and wider deployment in trauma and cardiovascular procedures. - The report defines hemostatic agents as medical substances that support the body’s clotting process, stop bleeding and help form a stable clot at the site of vessel injury. - In October 2025, UK Health Security Agency data showed 135,619 surgical operations recorded in 2023-24, with 1,276 surgical site infections identified during hospital stays or on readmission. - The UKHSA figure marked an 8.4% increase in reported operations from the previous year.

Between the lines: - The market story is less about one breakthrough and more about steady demand from routine and complex surgeries. - Product innovation appears to be shifting from basic clotting support toward combination and specialty-use formulations. - The regulatory emphasis on sterility and biocompatibility suggests suppliers will need to compete on both performance and compliance.

What's next: - Market growth will likely track surgical volumes, especially in minimally invasive, orthopedic, plastic and neurosurgery settings. - Adoption of advanced hemostats, biologically derived sealants and combination products is expected to keep expanding through 2030. - The report’s new 2026 features include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards and trend analysis.

The bottom line: - Hemostatic agents remain a niche medical category with broad surgical utility, and the report sees steady global expansion through the end of the decade.